Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748743 | 0.82 | MAP2K1 (0.43) | SYKKDRTEKEGFRRIPK2 | |
| SCHEMBL30749018 | 0.82 | SYK (0.40) | SYKKDRTEKEGFRRIPK2 | |
| SCHEMBL30748766 | 0.82 | KDR (0.45) | SYKKDRTEKEGFRRIPK2 | |
| SCHEMBL13166189 | 0.81 | STK17A (0.53) | KDRTEKEGFRRIPK2EPHB2 | |
| SCHEMBL30749092 | 0.78 | MEN1 (0.55) | KDRTEKEGFRKMT2APIN1 | |
| SCHEMBL30748907 | 0.78 | KDR (0.47) | SYKKDRTEKEGFRRIPK2 | |
| SCHEMBL30749081 | 0.78 | KDR (0.47) | SYKKDRTEKEGFRMAPT | |
| SCHEMBL16691353 | 0.77 | PIN1 (0.45) | EGFRKMT2APIN1 | |
| SCHEMBL30749000 | 0.76 | KDR (0.42) | KDRTEKEGFRRIPK2EPHB2 | |
| SCHEMBL30749054 | 0.75 | SMN1; SMN2 (0.51) | SYKKDRTEKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | SYK 2316/4885KDR 4605/4885TEK 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.